Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 42-45 , March 2009

An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid

Received 17 March 2008 ,Accepted 25 June 2008.

References 

  1. Storm G, Crommelin DJA. Liposomes: quo vadis?. Pharm Sci Technol Today. 1998;1:19–31
  2. Zheng J, Liu J, Dunne M, Jaffray DA, Allen C. In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res. 2007;24:1193–1201
  3. Zheng J, Perkins G, Kirilova A, Allen C, Jaffray DA. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest Radiol. 2006;41:339–348
  4. Kao C-Y, Hoffman EA, Beck KC, Bellamkonda RV, Annapragada AV. Long-residence-time nano-scale liposomal iohexol for X-ray-based blood pool imaging. Acad Radiol. 2003;10:475–483
  5. Mukundan S, Ghaghada KB, Badea CT, Kao C-Y, Hedlund LW, Provenzale JM, et al. A liposomal nanoscale contrast agent for preclinical CT in mice. Am J Roentgenol. 2006;186:300–307
  6. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004;100:135–144
  7. Nobs L, Buchegger F, Gurny R, Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93:1980–1992
  8. Park C-G, Thiex NW, Lee K-M, Szot GL, Bluestone JA, Lee K-D. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res. 2003;20:1239–1248
  9. Heasley VL, Shellhamer DF, Heasley LE, Yaeger DB, Heasley GE. Reactions of terminal alkynes with iodine in methanol. J Org Chem. 1980;45:4649–4652
  10. Hollins RA, Campos MPA. Stereochemistry of iodine addition to acetylenes. J Org Chem. 1979;44:3931–3934

 Research support came from the National Aeronautics and Space Administration (NNJ05HE75A) and the Department of Defense/Telemedicine and Advanced Technology Research Center (W81XWH-04-20035T5 and DAMD17-01-2-0047). Nuclear magnetic resonance facility support was provided by the National Cancer Institute Cancer Center Support Grant CA016672.

PII: S1549-9634(08)00092-0

doi: 10.1016/j.nano.2008.06.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 42-45 , March 2009

Article Tools

* Image Usage & Resolution